Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of plaque-type psoriasis for at least 6 months~* Patients with plaque-type psoriasis covering at least 10% of the body~Exclusion Criteria:~* Patients with nonplaque forms of psoriasis~* Patients who have current drug-induced psoriasis~* Patients who are pregnant, nursing, or planning pregnancy (both men and women) within 18 months of enrollment~* Patients who had any previous treatment with infliximab or any therapeutic agent targeted at reducing tumor necrosis factor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).